Compare VRCA & RBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | RBOT |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 17.9M |
| IPO Year | 2018 | N/A |
| Metric | VRCA | RBOT |
|---|---|---|
| Price | $5.71 | $1.98 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $17.00 | $7.00 |
| AVG Volume (30 Days) | ★ 116.1K | 58.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $372.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $1.71 |
| 52 Week High | $9.82 | $13.75 |
| Indicator | VRCA | RBOT |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 45.38 |
| Support Level | $5.34 | $1.76 |
| Resistance Level | $6.44 | $2.41 |
| Average True Range (ATR) | 0.42 | 0.20 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 52.71 | 38.63 |
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.